var data={"title":"Fluticasone (oral inhalation): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluticasone (oral inhalation): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7786?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluticasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (oral inhalation): Drug information&quot;</a> and <a href=\"topic.htm?path=fluticasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluticasone (oral inhalation): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349568\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ArmonAir RespiClick 113;</li>\n      <li>ArmonAir RespiClick 232;</li>\n      <li>ArmonAir RespiClick 55;</li>\n      <li>Arnuity Ellipta;</li>\n      <li>Flovent Diskus;</li>\n      <li>Flovent HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349569\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Arnuity Ellipta;</li>\n      <li>Flovent Diskus;</li>\n      <li>Flovent HFA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990183\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Inhalant (Oral)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12674645\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Bronchopulmonary dysplasia, treatment:</b> Oral Inhalation: See <b>Dosing: Usual</b> for dosing in infants (PNA in clinical trials &gt;28 days) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990189\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> <b>Note:</b> If adequate response is not seen after 2 weeks of initial dosage, increase dosage; doses should be titrated to the lowest effective dose once asthma is controlled: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Flovent HFA (Fluticasone propionate):</i> Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Initial: 88 mcg twice daily; maximum dose: 88 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Dosing based on previous asthma therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with bronchodilators alone: Initial: 88 mcg twice daily; maximum dose: 440 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients treated with an inhaled corticosteroid: Initial: 88 to 220 mcg twice daily; maximum dose: 440 mcg twice daily; may start doses above 88 mcg twice daily in poorly controlled patients or in those who previously required higher doses of inhaled corticosteroids </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with oral corticosteroids: 440 mcg twice daily; maximum dose: 880 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asthma Guidelines: National Asthma Education and Prevention Program guidelines (NAEPP 2007): HFA inhaler (refers to Flovent HFA 44 mcg, 110 mcg, and 220 mcg strength): <b>Note:</b> Administer in divided doses twice daily: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Low&quot; dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;4 years: 176 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years: 88 to 176 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 88 to 264 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;Medium&quot; dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;11 years: &gt;176 to 352 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: &gt;264 to 440 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&quot;High&quot; dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;11 years: &gt;352 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: &gt;440 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Flovent Diskus (Fluticasone propionate):</i> Oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled if not already receiving maximum dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Patients previously treated with bronchodilators alone or inhaled corticosteroids: Initial: 50 mcg twice daily; may increase to maximum dose of 100 mcg twice daily; initial dose &gt;50 mcg twice daily may be considered in patients poorly controlled or in those who previously required higher doses of inhaled corticosteroids</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with bronchodilators alone: Initial: 100 mcg twice daily; maximum dose: 500 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with inhaled corticosteroids: Initial: 100 to 250 mcg twice daily; maximum dose: 500 mcg twice daily; initial dose &gt;100 mcg twice daily may be considered in poorly controlled patients or in those who previously required higher doses of inhaled corticosteroids </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with oral corticosteroids: Initial: 500 to 1,000 mcg twice daily (select dose based on assessment of individual patient); maximum dose: 1,000 mcg twice daily; <b>Note:</b> Inability to reduce oral corticosteroid therapy may indicate need for maximum fluticasone dose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asthma Guidelines:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Asthma Education and Prevention Program Guidelines (NAEPP 2007): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths): <b>Note:</b> Administer in divided doses twice daily: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 200 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;200 to 400 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;400 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 300 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;300 to 500 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;500 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Global Initiative for Asthma Guidelines (GINA 2015): Dry powder inhaler (refers to Flovent Diskus 50 mcg, 100 mcg, and 250 mcg strengths available) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 11 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 200 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;200 to 400 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ldquo;High&quot; dose: &gt;400 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge; 12 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Low&quot; dose: 100 to 250 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;Medium&quot; dose: &gt;250 to 500 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&quot;High&quot; dose: &gt;500 mcg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Arnuity Ellipta (fluticasone furoate): </i>Children &ge;12 years and Adolescents: Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">No prior treatment with inhaled corticosteroids: Initial: 100 mcg once daily; maximum: 200 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior treatment with inhaled corticosteroids: Initial: 100 to 200 mcg once daily; maximum: 200 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conversion from oral systemic corticosteroids to orally inhaled corticosteroids:</i> When converting from oral corticosteroids (OCS) to orally inhaled corticosteroids, initiate oral inhalation therapy in patients whose asthma is previously stabilized on OCS. Gradual OCS dose reductions should begin after at least 7 days after starting inhaled therapy. Manufacturer's labeling recommends reducing prednisone dose no more rapidly than 2.5 to 5 mg/day (or equivalent of other OCS) weekly in children &ge;12 years but does not provide a recommendation for children &lt;12 years. A similar approach to OCS dose reduction would, however, seem advisable. If adrenal insufficiency occurs, resume OCS therapy; initiate a more gradual withdrawal. When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchopulmonary dysplasia, treatment</b>: Limited data available: Infants: Fluticasone propionate: Oral inhalation: Some centers have used 2 to 4 puffs (44 mcg/puff) every 12 hours via a face mask and a spacer. One trial used fixed doses administered via a spacer and neonatal anesthesia bag (into ventilator, directly into nasopharyngeal endotracheal tube, or with a face mask) in 16 former preterm neonates (GA: &le;32 weeks; PNA: 28 to 60 days); chest radiograph score was improved compared to placebo; the treatment group had increased blood pressure compared to baseline; the authors conclude that the trial results do not support the use of fluticasone in oxygen-dependent patients with moderate BPD; exact dosing cannot be replicated in the US with available products (Dugas 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.5 to 1.2 kg: 125 mcg every 12 hours for 3 weeks, followed by 125 mcg once daily for the 4th week </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;1.2 kg: 250 mcg every 12 hours for 3 weeks, followed by 250 mcg once daily for the 4th week </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Eosinophilic esophagitis:</b> Limited data available: Oral (swallowed): <b>Note:</b> Patients use an oral inhaler without a spacer and swallow the medication. Optimal dose and dosing regimen are not established: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">A randomized, double-blind, placebo-controlled trial (n=31) demonstrated efficacy by assessment of histologic remission (Konikoff 2006): Children: 3 to 16 years: 440 mcg twice daily for 3 months </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">A prospective, randomized trial (n=80) compared swallowed fluticasone to oral prednisone; a greater degree of improvement in histologic response was seen in the prednisone group; however, no difference in clinical response was observed between the two groups; esophageal candidiasis occurred more frequently in patients receiving fluticasone (Schaffer 2008): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: 1 to 10 years: 220 mcg 4 times daily for 4 weeks, 220 mcg 3 times daily for 3 weeks, 220 mcg twice daily for 3 weeks, 220 mcg daily for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 11 to 18 years: 440 mcg 4 times daily for 4 weeks, 440 mcg 3 times daily for 3 weeks, 440 mcg twice daily for 3 weeks, 440 mcg daily for 2 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Oral Inhalation: <b>Note:</b> Titrate to the lowest effective dose once asthma stability is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arnuity Ellipta (fluticasone furoate): Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">No prior treatment with inhaled corticosteroids: Initial: 100 mcg once daily; maximum: 200 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior treatment with inhaled corticosteroids: Initial: 100 to 200 mcg once daily; maximum: 200 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flovent HFA (fluticasone propionate): Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bronchodilator alone: Initial: 88 mcg twice daily; maximum: 440 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhaled corticosteroids: Initial: 88 to 220 mcg twice daily (initial dose &gt;88 mcg twice daily may be considered in patients previously requiring higher doses of inhaled corticosteroids); maximum: 440 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral corticosteroids (OCS): Initial: 440 mcg twice daily; maximum: 880 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flovent Diskus (fluticasone propionate): Dosing based on previous asthma therapy: <b>Note:</b> May increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bronchodilator alone: Initial: 100 mcg twice daily; maximum: 500 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inhaled corticosteroids: Initial: 100 to 250 mcg twice daily; maximum: 500 mcg twice daily; initial dose &gt;100 mcg twice daily may be considered in patients with poorer asthma control or those previously requiring high ranges of inhaled corticosteroids </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral corticosteroids (OCS): Initial: 500 to 1,000 mcg twice daily; maximum: 1,000 mcg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion: Conversion from oral systemic corticosteroids to orally inhaled corticosteroids:</b> When converting from oral corticosteroids (OCS) to orally inhaled corticosteroids, initiate oral inhalation therapy in patients whose asthma is previously stabilized on OCS. Gradual OCS dose reductions should begin ~7 days after starting inhaled therapy. Manufacturer's labeling recommends reducing prednisone dose no more rapidly than 2.5 to 5 mg/day (or equivalent of other OCS) weekly. If adrenal insufficiency occurs, resume OCS therapy; initiate a more gradual withdrawal. When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Arnuity Ellipta (Fluticasone furoate): Children &ge;12 years, Adolescents, and Adults: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus and Flovent HFA (Fluticasone propionate): There are no dosage adjustment provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b> There are no dosage adjustment provided in the manufacturer's labeling (has not been studied); however, fluticasone is primarily eliminated in the liver and serum concentrations may be elevated in patients with hepatic impairment. Use with caution and closely monitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242572\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol, Inhalation, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flovent HFA: 44 mcg/actuation (10.6 g); 110 mcg/actuation (12 g); 220 mcg/actuation (12 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arnuity Ellipta: 100 mcg/actuation (14 ea, 30 ea); 200 mcg/actuation (14 ea, 30 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Powder Breath Activated, Inhalation, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 55: 55 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 232: 232 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ArmonAir RespiClick 113: 113 mcg/actuation (1 ea) [contains lactose monohydrate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flovent Diskus: 50 mcg/blister (60 ea); 100 mcg/blister (28 ea, 60 ea); 250 mcg/blister (28 ea, 60 ea) [contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349571\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005910\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-oral-inhalation-drug-information\" class=\"drug drug_general\">see &quot;Fluticasone (oral inhalation): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Flovent HFA 10.6 g and 12 g canisters contain 120 inhalations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10495266\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral inhalation: Rinse mouth with water (without swallowing) after inhalation to decrease chance of oral candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol inhalation: Flovent HFA (Fluticasone propionate): Shake canister well for 5 seconds before each spray; use at room temperature. Inhaler must be primed before first use with four test sprays (spray into air away from face, shake well for 5 seconds between sprays) and primed again with one test spray if not used for &gt;7 days or if dropped. Use a spacer device for children &lt;8 years of age. Patient should contact pharmacy for refill when the dose counter reads &quot;020.&quot; Discard device when the dose counter reads &quot;000.&quot; Do not try to alter numbers on counter or remove the counter from the metal canister. Do not immerse canister into water (ie, do not use &quot;float test&quot; to determine contents).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Arnuity Ellipta (Fluticasone furoate): Administer the dose at the same time every day. Do not shake inhaler. When ready to use, open and prepare mouthpiece of the inhaler and slide the cover down to activate the first dose. Exhale fully (not into mouthpiece), take one deep breath through mouth without blocking air vents and hold breath for about 3 to 4 seconds. If the cover is opened and closed without inhaling the medicine, the dose will be lost. The lost dose will be held in the inhaler, but it will no longer be available to be inhaled. It is not possible to accidentally take a double dose or an extra dose in one inhalation. Routine cleaning of the inhaler is not required; may clean the mouthpiece if needed, using a dry tissue, before the cover is closed. Discard inhaler after 30 sprays or when the counter reads &quot;0&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flovent Diskus (Fluticasone propionate): Do not use with spacer device; do not exhale into Diskus; do not wash or take apart; activate and use Diskus in horizontal position. Discard after 6 weeks (50 mcg diskus) or after 2 months (100 mcg and 250 mcg diskus) once removed from protective pouch or when the dose counter reads &ldquo;0&rdquo;, whichever comes first (device is not reusable). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (swallowed): <b>Note:</b> This method of administration is for treatment of eosinophilic esophagitis only. Use metered dose inhaler. Do not use a spacer. Shake canister well for 5 seconds before each spray. Prime inhaler as outlined above. Actuate inhaler and spray medication into pharynx; swallow the medication (rather than inhale). Do not eat, drink, or rinse mouth for 30 minutes following administration (Konikoff 2006; Schaefer 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349613\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metered dose inhaler (fluticasone propionate [aerosol]): Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard device when the dose counter reads &quot;000.&quot; Store with mouthpiece down. Do not expose to temperatures greater than 48.8&deg;C (120&deg;F). Do not puncture or incinerate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dry powder inhaler (fluticasone furoate and fluticasone propionate [Diskus]): Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in a dry place away from direct heat or sunlight. Discard after 6 weeks (50 mcg Diskus and Arnuity Ellipta), after 2 months (100 and 250 mcg Diskus), or after 30 days (ArmonAir Respiclick) from removal from protective foil pouch or when the dose counter reads &quot;0&quot; (whichever comes first); device is not reusable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990184\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arnuity Ellipta: Maintenance treatment of asthma as prophylactic therapy (FDA approved in patients &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flovent Diskus, Flovent HFA: Maintenance treatment of asthma as prophylactic therapy (including patients who require corticosteroids and those who may benefit from a dose reduction/elimination of systemically administered corticosteroids) (FDA approved in patients &ge;4 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Not</b> indicated for the relief of acute bronchospasm. Has also been used for the treatment of BPD and orally (swallowed; using metered dose inhaler) for eosinophilic esophagitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349564\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Arnuity Ellipta may be confused with Anoro Ellipta, Breo Ellipta, and Incruse Ellipta; Ellipta is the inhaler delivery system trademark not a medication</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flovent may be confused with Flonase</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flovent [US, Canada] may be confused with Flogen brand name for naproxen [Mexico]; Flogene brand name for piroxicam [Brazil]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349583\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension, subarachnoid hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache, malaise, pain, procedural pain, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, gastrointestinal distress, gastrointestinal pain, nausea and vomiting, oral candidiasis, oropharyngeal candidiasis, toothache, viral gastroenteritis, viral gastrointestinal infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Malignant neoplasm of breast</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, influenza, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, herniated disk, muscle injury, musculoskeletal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Allergic rhinitis, bronchitis, cough, hoarseness, nasal congestion, nasopharyngitis, oropharyngeal pain, pharyngitis, rhinitis, sinus infection, sinusitis, throat irritation, upper respiratory tract infection, upper respiratory tract inflammation, viral respiratory infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Accidental injury, amputation, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aggressive behavior, agitation, allergic skin reaction, anaphylaxis, anxiety, aphonia, arthritis, behavioral changes, bronchospasm, bruise, burn, cataract, chest symptoms, chest tightness, Cushingoid appearance, decreased linear skeletal growth rate, dental caries, dental discoloration, dental discomfort, depression, diarrhea, dizziness, dyspepsia, dyspnea, ecchymoses, epistaxis, esophageal candidiasis, exacerbation of asthma, facial edema, gastrointestinal disease, hyperglycemia, hypersensitivity reaction (musculoskeletal), laryngitis, migraine, mood disorder, mouth disease, oropharyngeal edema, osteonecrosis, osteoporosis, paradoxical bronchospasm, pneumonia, restlessness, rhinorrhea, soft tissue injury, sore throat, urinary tract infection, weight gain, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349579\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluticasone or any component of the formulation; severe hypersensitivity to milk proteins or lactose (ArmonAir Respiclick, Arnuity Ellipta, Flovent Diskus); primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Flovent HFA and Flovent Diskus: Untreated fungal, bacterial or tubercular infections of the respiratory tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349580\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis in sensitive patients. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled corticosteroids due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Select surgical patients on long-term, high-dose, inhaled corticosteroid (ICS), should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Immediate hypersensitivity reactions (eg, angioedema, bronchospasm, hypotension, rash, urticaria), including anaphylaxis, may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent tuberculosis infections of the respiratory tract; or viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox and measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. With oral inhalation, local yeast infections (eg, oropharyngeal candidiasis) may occur; patient should rinse mouth with water and spit after each use to reduce incidence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while continuing fluticasone therapy. Patients should be instructed to rinse mouth with water without swallowing after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Short-acting beta<sub>2</sub>-agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Not to be used in status asthmaticus or for the relief of acute bronchospasm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention. Impairment of liver function may lead to accumulation of fluticasone in plasma. Monitor patients for corticosteroid related adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ArmonAir Respiclick, Arnuity Ellipta, and Flovent Diskus: May contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of systemic corticosteroids: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 to 5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transfer to oral inhaler: When transferring to oral inhaler, previously suppressed allergic conditions (arthritis, rhinitis, conjunctivitis, eczema, eosinophilic conditions) may be unmasked.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349606\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15933&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation). Management: Use of orally inhaled fluticasone propionate with strong CYP3A4 inhibitors is not recommended.  Use of orally inhaled fluticasone furoate with strong CYP3A4 inhibitors should be done with caution.  Monitor patients using such a combination more closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349575\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy (Battista 2016). Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications (ACOG 2008; GINA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy (ACOG 2008; GINA 2016; Namazy 2016). Pregnant females adequately controlled on fluticasone for asthma may continue therapy; if initiating treatment during pregnancy, use of an agent with more data in pregnant females may be preferred (Namazy 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F990190\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor growth in pediatric patients (via stadiometry). Check mucus membranes for signs of fungal infection. Monitor for symptoms of asthma, FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; HPA axis suppression; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma); bone mineral density; possible eosinophilic conditions (including Churg-Strauss syndrome) and for hepatic impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242564\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity. The effectiveness of inhaled fluticasone is due to its direct local effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349615\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximal benefit may take 1 to 2 weeks or longer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Absorbed systemically primarily via lungs (Flovent Diskus: ~18%); minimal GI absorption (&lt;1%) due to presystemic metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 4.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to 17&beta;-carboxylic acid (negligible activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral inhalation: 13.9%; Flovent Diskus: ~8%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~8 hours; Oral inhalation (plasma elimination phase following repeat dosing): 24 hours (ArmonAir Respiclick: ~11.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (as parent drug and metabolites); urine (&lt;5% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349664\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Flovent HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">44 mcg/ACT (10.6 g): $218.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">110 mcg/ACT (12 g): $291.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 mcg/ACT (12 g): $453.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 113 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113 mcg/ACT (1): $271.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 232 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">232 mcg/ACT (1): $271.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (ArmonAir RespiClick 55 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55 mcg/ACT (1): $203.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Arnuity Ellipta Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/ACT (14): $94.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/ACT (14): $126.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Flovent Diskus Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/blister (60): $206.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/blister (28): $126.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg/blister (28): $170.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12707662\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allegro (IL);</li>\n      <li>Allevisone (TW);</li>\n      <li>Arnuity (JP);</li>\n      <li>Arnuity Ellipta (SG);</li>\n      <li>Atemur Mite (DE);</li>\n      <li>Axotide (CH);</li>\n      <li>Dalman AQ (HK);</li>\n      <li>Flixotaide (PT);</li>\n      <li>Flixotide (AE, AR, AT, BE, BG, BH, BR, CL, CN, CR, CY, CZ, DK, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KR, KW, LB, LT, LU, LV, LY, MT, MY, NI, NL, NZ, OM, PA, PE, PH, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE, ZW);</li>\n      <li>Flixotide Inhaler (AU);</li>\n      <li>Flixotide Nebules (AU);</li>\n      <li>Flixovate (FR);</li>\n      <li>Flohale (AE, ZW);</li>\n      <li>Flomist (MY);</li>\n      <li>Flutaide (PT);</li>\n      <li>Flutica (DE);</li>\n      <li>Flutico (BD);</li>\n      <li>Flutide (DE, SE);</li>\n      <li>Flutimar HFA (CO);</li>\n      <li>Flutitrim (SG);</li>\n      <li>Flutivate (BR, DE);</li>\n      <li>Futisone (TW);</li>\n      <li>Lutisone (HK);</li>\n      <li>Medicort (ID);</li>\n      <li>Meseca (VN);</li>\n      <li>Nasofan (HK);</li>\n      <li>Rheoran F (LK);</li>\n      <li>Zoflut (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 90, February 2008: Asthma in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2008, 111(2 Pt 1):457-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/18238988/pubmed\" target=\"_blank\" id=\"18238988\">18238988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnuity Ellipta (fluticasone furoate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and Fetal Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2005, 116(3):503-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/16159616/pubmed\" target=\"_blank\" id=\"16159616\">16159616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dugas MA, Nguyen D, Frenette L, et al, &quot;Fluticasone Inhalation in Moderate Cases of Bronchopulmonary Dysplasia,&quot; <i>Pediatrics</i>, 2005, 115(5):566-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/15833887/pubmed\" target=\"_blank\" id=\"15833887\">15833887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent Diskus (fluticasone propionate inhalation powder) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flovent HFA (fluticasone propionate inhalation aerosol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fok TF, Lam K, Dolovich M, et al, &quot;Randomised Controlled Study of Early Use of Inhaled Corticosteroid in Preterm Infants With Respiratory Distress Syndrome,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 1999, 80(3):203-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/10212082/pubmed\" target=\"_blank\" id=\"10212082\">10212082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). GINA report, global strategy for asthma management and prevention. 2015. Available at http://www.ginasthma.org/documents/4. Updated April 2015. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konikoff MR, Noel RJ, Blanchard C, et al, &quot;A Randomized, Double-Blind, Placebo-Controlled Trial of Fluticasone Propionate for Pediatric Eosinophilic Esophagitis,&quot; <i>Gastroenterology</i>, 2006, 131(5):1381-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/17101314/pubmed\" target=\"_blank\" id=\"17101314\">17101314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo; <i>J Allergy Clin Immunol</i>, 2004, 113(3):427-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/15007341/pubmed\" target=\"_blank\" id=\"15007341\">15007341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP) Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at <a href=\"http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng PC, Fok TF, Liu F, et al, &quot;Effects of Inhaled Corticosteroids on Systemic Blood Pressure in Preterm Infants,&quot; <i>Biol Neonate</i>, 2004, 86(3):201-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/15249756/pubmed\" target=\"_blank\" id=\"15249756\">15249756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaffer ET, Fitzgerald JF, Molleston JP, et al, &quot;Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children,&quot; <i>Clin Gastroenterol Hepatol</i>, 2008, 6(2):165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-oral-inhalation-pediatric-drug-information/abstract-text/18237866/pubmed\" target=\"_blank\" id=\"18237866\">18237866</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15933 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9349568\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9349569\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F990183\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12674645\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F990189\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242572\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9349571\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005910\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10495266\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9349613\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F990184\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9349564\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9349583\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9349579\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9349580\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9349607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9349606\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9349575\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F990190\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F242564\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9349615\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9349664\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12707662\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15933|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluticasone-oral-inhalation-drug-information\" class=\"drug drug_general\">Fluticasone (oral inhalation): Drug information</a></li><li><a href=\"topic.htm?path=fluticasone-oral-inhalation-patient-drug-information\" class=\"drug drug_patient\">Fluticasone (oral inhalation): Patient drug information \t</a></li></ul></div></div>","javascript":null}